Rongxia Liu1, Elke H Heiss2, Daniel Schachner2, Baohong Jiang3, Wanhui Liu1, Johannes M Breuss4, Verena M Dirsch2, Atanas G Atanasov2,5. 1. School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University , Yantai, 264005, People's Republic of China. 2. Department of Pharmacognosy, University of Vienna , Vienna, 1090, Austria. 3. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai, 201203, People's Republic of China. 4. Center for Physiology and Pharmacology, Institute for Vascular Biology and Thrombosis Research, Medical University of Vienna , Vienna, 1090, Austria. 5. Institute of Genetics and Animal Breeding of the Polish Academy of Sciences , 05-552 Jastrzebiec, Poland.
Abstract
Xanthohumol (1) is a principal prenylated chalcone found in hops. The aim of this study was to examine its influence on platelet-derived growth factor (PDGF)-BB-triggered vascular smooth muscle cell (VSMC) proliferation and migration in vitro and on experimentally induced neointima formation in vivo. Quantification of resazurin conversion indicated that 1 can inhibit PDGF-BB-induced VSMC proliferation concentration-dependently (IC50 = 3.49 μM). Furthermore, in a wound-healing assay 1 potently suppresses PDGF-BB-induced VSMC migration at 15 μM. Tested in a mouse femoral artery cuff model, 1 significantly reduces neointima formation. Taken together, we show that 1 represses PDGF-BB-induced VSMC proliferation and migration in vitro as well as neointima formation in vivo. This novel activity suggests 1 as an interesting candidate for further studies addressing a possible therapeutic application to counteract vascular proliferative disease.
Xanthohumol (1) is a principal prenylated chalcone found in hops. The aim of this study was to examine its influence on platelet-derived growth factor (PDGF)-BB-triggered vascular smooth muscle cell (VSMC) proliferation and migration in vitro and on experimentally induced neointima formation in vivo. Quantification of resazurin conversion indicated that 1 can inhibit PDGF-BB-induced VSMC proliferation concentration-dependently (IC50 = 3.49 μM). Furthermore, in a wound-healing assay 1 potently suppresses PDGF-BB-induced VSMC migration at 15 μM. Tested in a mouse femoral artery cuff model, 1 significantly reduces neointima formation. Taken together, we show that 1 represses PDGF-BB-induced VSMC proliferation and migration in vitro as well as neointima formation in vivo. This novel activity suggests 1 as an interesting candidate for further studies addressing a possible therapeutic application to counteract vascular proliferative disease.
Cardiovascular disease (CVD) remains
a leading cause of morbidity and mortality in the world, despite recent
improvements in therapeutic approaches.[1,2] It is primarily
caused by atherosclerosis and kept in check by cardiovascular interventions
including angioplasty, stenting, and bypass, which are already widely
used in clinics.[3] However, restenosis (renarrowing)
of surgically dilated arteries occurs with high rates and is a very
serious complication of these interventions. The pathology of atherosclerosis
and restenosis involves primarily intimal hyperplasia, due to proliferation
and migration of vascular smooth muscle cells (VSMCs).[4] This pathological process is started by vessel injury,
which triggers a series of inflammatory responses controlled by various
circulating growth factors and inflammatory cytokines.[5−7] Of the involved injury-induced factors, platelet-derived growth
factor-BB (PDGF-BB) has been reported as the most potent inducer of
VSMC proliferation and migration.[7] The
abnormal VSMC proliferation and migration lead to neointima formation
and eventually result in arterial lumen narrowing.[8,9] Thus,
to prevent neointima hyperplasia, one good strategy is to inhibit
PDGF-BB-induced proliferation and migration of VSMCs.Plant-derived
natural products proved to be an excellent resource for the identification
of new lead compounds.[10,11] Hops, the cones from Humulus lupulus L., are used in the brewing industry to
flavor beer and also in folk medicine. Many pharmacological activities
have been reported for this plant, including sedative, estrogenic,
anticancer,
antibacterial, and cardioprotective properties.[12,13] Xanthohumol (1; Figure ), a major bioactive constituent of hops, possesses
anti-inflammatory, antioxidant, anticancer, antiobesity, and hepatoprotective
activities.[14−16] Regarding an influence on the (cardio)vascular system, 1 hinders angiogenesis presumably by inhibition of nuclear
factor-kB- and growth factor-induced AKT signaling.[17−19] It also prevents
platelet activation and aggregation, with an apparent contribution
of diminished AKT, p38, and PLCγ2/PKC signaling as well as reduced
thromboxane 2 formation and [Ca2+]i.[20−22] A modulated calcium signaling may also account for potential antiarrhythmic
properties of 1.[23] Furthermore,
inhibition of cholesteryl ester transfer protein and promotion of
reverse cholesterol transport afford protection from atherosclerosis
by 1.[24,25] Despite these promising data
in relevant test systems, the potential impact of 1 on
intimal hyperplasia has not been the focus of any study so far.
Figure 1
Chemical structure
of xanthohumol.
Chemical structure
of xanthohumol.Thus, the present study
aimed to investigate the effects of 1 on PDGF-BB-induced
VSMC proliferation and migration in vitro, as well
as its influence on neointima formation in vivo.In order to test whether 1 is able to inhibit growth-factor-induced
proliferation of VSMCs, its influence on the total cellular metabolic
activity of VSMCs was measured by the resazurin conversion method.
PDGF-BB was used as a promitogenic stimulus in this study. Total metabolic
activity was measured 48 h after PDGF-BB treatment of VSMCs, which
were already preincubated with vehicle or 1 (1–15
μM) for 30 min. Indeed, 1 inhibited PDGF-BB-induced
VSMC proliferation concentration dependently, with an IC50 value of 3.49 μM (Figure A). To ensure that the decreased VSMC number upon treatment
with 1 is due to proliferation inhibition and not cytotoxicity,
we quantified cytosolic lactate dehydrogenase (LDH) inside the cells
and in cell supernatants upon exposure to 1. No significant
cytotoxicity was detected in the investigated concentration range
(Figure B).
Figure 2
Xanthohumol
(XN) inhibits PDGF-BB-induced VSMC proliferation. Quiescent VSMCs
were pretreated with the indicated concentrations of xanthohumol (1–15
μM) or an equal volume of the solvent vehicle (0.1% DMSO) for
30 min and then stimulated with 20 ng/mL PDGF-BB for 48 h. (A) The
metabolic activity was determined at the end of the stimulation period
by the resazurin conversion method. All values are normalized to the
signal obtained from the PDGF-BB-stimulated, vehicle-treated cells.
(B) The cytotoxicity was assessed by quantification of % extracellular
LDH activity as described in the Experimental Section. Digitonin (50 μg/mL) was used as a positive cytotoxic control.
The data groups represent means ± SD from three independent experiments
(***p < 0.001; n.s., not significant; vs PDGF-BB-stimulated
cells; ANOVA/Bonferroni).
Xanthohumol
(XN) inhibits PDGF-BB-induced VSMC proliferation. Quiescent VSMCs
were pretreated with the indicated concentrations of xanthohumol (1–15
μM) or an equal volume of the solvent vehicle (0.1% DMSO) for
30 min and then stimulated with 20 ng/mL PDGF-BB for 48 h. (A) The
metabolic activity was determined at the end of the stimulation period
by the resazurin conversion method. All values are normalized to the
signal obtained from the PDGF-BB-stimulated, vehicle-treated cells.
(B) The cytotoxicity was assessed by quantification of % extracellular
LDH activity as described in the Experimental Section. Digitonin (50 μg/mL) was used as a positive cytotoxic control.
The data groups represent means ± SD from three independent experiments
(***p < 0.001; n.s., not significant; vs PDGF-BB-stimulated
cells; ANOVA/Bonferroni).To investigate whether 1 can also inhibit PDGF-BB-induced
VSMC migration, we performed a wound-healing assay in the presence
of 1. After preincubation with vehicle or 1 (5 or 15 μM) for 30 min, the scratched VSMCs were treated
with PDGF-BB and incubated for the next 20 h. Photos of the “wound”
in the VSMC monolayer at the beginning (t = 0 h)
and the end (t = 20 h) were taken, and the cell recolonization
rate was analyzed. Upon stimulation with PDGF-BB, control cells were
able to significantly recover the cell-free area (∼3.5-fold
compared to unstimulated cells). Co-treatment with 15 μM 1 showed potent inhibition of PDGF-induced VSMC migration,
allowing cell motility only in the range of the basal unstimulated
control group (Figure ).
Figure 3
Xanthohumol (XN) prevents PDGF-BB-induced VSMC migration. In a wound-healing
assay, VSMCs were pretreated with the indicated concentrations of
xanthohumol or an equal volume of the solvent vehicle (0.1% DMSO)
for 30 min and then stimulated with 10 ng/mL PDGF-BB. (A) Photos of
the “wound” in the VSMC monolayer at the beginning (t = 0 h) and the end (t = 20 h) of the
stimulation period (light microscopy, magnification 100×). (B)
Graph indicating the change in the area occupied by cells as fold
induction of VSMC migration from three independent biological replicates
with four technical replicates each; means ± SD (***p < 0.001; n.s., not significant; vs PDGF-BB-stimulated cells;
ANOVA/Bonferroni).
Xanthohumol (XN) prevents PDGF-BB-induced VSMC migration. In a wound-healing
assay, VSMCs were pretreated with the indicated concentrations of
xanthohumol or an equal volume of the solvent vehicle (0.1% DMSO)
for 30 min and then stimulated with 10 ng/mL PDGF-BB. (A) Photos of
the “wound” in the VSMC monolayer at the beginning (t = 0 h) and the end (t = 20 h) of the
stimulation period (light microscopy, magnification 100×). (B)
Graph indicating the change in the area occupied by cells as fold
induction of VSMC migration from three independent biological replicates
with four technical replicates each; means ± SD (***p < 0.001; n.s., not significant; vs PDGF-BB-stimulated cells;
ANOVA/Bonferroni).We then examined whether 1 can also prevent neointima formation in vivo. The mouse femoral artery cuff model represents an animal model
used to examine vessel responses to injury that are relevant for restenosis.[26−28] The femoral artery cuff placement leads to predictable neointima
formation in mice over a 14-day period.[28] To assess the effect of locally applied 1 on the cuff-induced
restenosis, 1 was dissolved in F-127 gel and placed in
the cuff surrounding the femoral artery. Compared to sham-operated
vessels, injured vessels displayed significant neointima formation
14 days after the cuff placement, which could be significantly attenuated
by treatment with 1 (Figure ).
Figure 4
Xanthohumol (XN) suppresses neointima formation in vivo. A nonconstructive polyethylene cuff filled with
F-127 pluronic gel containing xanthohumol or vehicle was placed loosely
around the right femoral artery of mice. For the sham-operated group,
the right femoral artery was dissected from surrounding tissues, but
a cuff was not placed. (A) Representative photomicrograph of hematoxylin
and eosin staining cross sections in femoral arteries at day 14: sham-operated
control, cuff injured control, and cuff injured with XN treatment.
(B–D) Quantitative analysis of the neointima cross-sectional
area, the media cross-sectional area, and the neointima to media cross-sectional
ratio. Data are shown as the mean ± SD, at least six experimented
mice per group, and Student’s t-test was used
to compare the difference between groups. ***p <
0.001; n.s., not significant; vs cuff-injured control. Scale bars,
50 μm.
Xanthohumol (XN) suppresses neointima formation in vivo. A nonconstructive polyethylene cuff filled with
F-127 pluronic gel containing xanthohumol or vehicle was placed loosely
around the right femoral artery of mice. For the sham-operated group,
the right femoral artery was dissected from surrounding tissues, but
a cuff was not placed. (A) Representative photomicrograph of hematoxylin
and eosin staining cross sections in femoral arteries at day 14: sham-operated
control, cuff injured control, and cuff injured with XN treatment.
(B–D) Quantitative analysis of the neointima cross-sectional
area, the media cross-sectional area, and the neointima to media cross-sectional
ratio. Data are shown as the mean ± SD, at least six experimented
mice per group, and Student’s t-test was used
to compare the difference between groups. ***p <
0.001; n.s., not significant; vs cuff-injured control. Scale bars,
50 μm.Aberrant VSMC proliferation
and migration are major events in atherosclerosis and restenosis progression.
Therefore, identification of phytochemicals able to suppress VSMC
proliferation and migration is of potential therapeutic relevance.
Hops have been widely used since ancient times not only in the manufacturing
of beer, but also as a medicinal plant. As the most abundant prenylated
flavonoid in hops, 1 attracts an increasing amount of
attention due to a variety of newly described health-promoting activities.
To our knowledge, the present study is the first to show that 1 also suppresses proliferation and migration of PDGF-BB-induced
VSMCs in vitro and reduces neointima formation in vivo. Further studies will be necessary to dissect the
underlying molecular mode of action. Due to its electrophilic nature, 1 directly affects several cellular targets and signaling
pathways[29] and modulates activity of kinases,
such as Akt and AMPK, and of transcription factors, such as Nrf2,
NF-kB, or STAT3.[19,30,31] All those signaling molecules may conceivably contribute to the
reduced neointima formation. Therefore, it is highly likely that the
antihyperplastic
effect of 1 observed in this study cannot be pinned down
to one single molecular target or pathway but rather exploits the
pronounced polypharmacology of 1.
Experimental
Section
General Experimental Procedures
In this study, rat
aortic VSMCs, growth media, and cell culture supplements were purchased
from Lonza (Basel, Switzerland). Serum for cell culture was obtained
from Gibco Life Technologies (Darmstadt, Germany), and PDGF-BB was
supplied from Bachem (Weilheim, Germany). Compound 1 and
the other used reagents were obtained from Sigma-Aldrich (Shanghai,
China).
Cell Culture and VSMC Proliferation
VSMCs were cultivated
in Dulbecco’s modified essential medium (DMEM)–F12 (1:1)
supplemented with 20% fetal calf serum (FCS), 30 μg/mL gentamicin,
and 15 ng/mL amphotericin B at 37 °C in an incubator with 5%
CO2 flow in a humidified atmosphere.Cell proliferation
was assessed by resazurin conversion assay, as described previously.[32−35] Briefly, VSMCs were seeded at a density of 5 × 103 cells/well in 96-well plates. After 24 h, cells were serum-starved
for another 24 h to render them quiescent. Quiescent cells were pretreated
for 30 min with 0.1% DMSO or 1 at the indicated concentrations
and subsequently stimulated with PDGF-BB (20 ng/mL) for 48 h. Then,
after washing the cells with phosphate-buffered saline (PBS), they
were incubated in serum-free medium containing resazurin (10 μg/mL)
for 2 h. The amount of metabolically active VSMCs was determined by
the increased fluorescence yield from the conversion of resazurin.
Samples were measured by monitoring the increase in fluorescence at
590 nm using an excitation wavelength of 535 nm in a 96-well plate
reader (Tecan GENios Pro) from Tecan Group Ltd. (Männedorf,
Switzerland).
Assessment of Cytotoxicity
Cytotoxicity
was evaluated by detection of the release of LDH.[32,36] VSMCs were incubated and treated with the same procedure as for
the cell proliferation assay. The supernatants of the treated cells
were measured for the released soluble LDH activity. For determination
of the total LDH activity, identically treated samples were incubated
for 45 min with 1% Triton X-100. The released and total LDH enzyme
activity was determined for 30 min in the dark in the presence of
4.5 mg/mL lactate, 0.56 mg/mL NAD+, 1.69 U/mL diaphorase, 0.004% (w/v)
BSA, 0.15% (w/v) sucrose, and 0.5 mM 2-p-iodophenyl-3-nitrophenyl
tetrazolium chloride. The
absorbance was detected at 490 nm after the enzyme reaction was stopped
with 1.78 mg/mL Oxymate. Percentage of extracellular LDH enzyme activity
was calculated to estimate the potential effects on cell viability.
The cytotoxic compound digitonin (50 μg/mL) was used as a positive
control.
Wound-Healing Assay (Scratch Assay)
The scratch assay
was performed as previously described.[37−39] Briefly, VSMCs were
seeded in six-well plates, grown to confluence, and starved for 24
h. The cell monolayer was scratched using a sterile pipet tip (1000
μL)
with the scratch width around 1 mm. Cells were recovered for the next
24 h in freshly exchanged starvation medium (0.1% serum supplemented
DMEM-F12). Then, 0.1% DMSO or 1 at the indicated concentrations
was applied to the cells, and 30 min later, PDGF-BB (10 ng/mL) was
also applied. VSMCs were then incubated for the next 20 h, and potential
influence on migration was monitored. Photographs of the scratch under
the light microscope (Olympus CKX41, Tokyo, Japan, magnification 100×)
were taken at 0 and 20 h after the treatment. Perpendicular lines
were predrawn at the bottom side of the plates to ensure that the
very same area of each scratch is captured at 0 and 20 h. The cell
recolonization
rate was recorded by measuring the cell-free area of each scratch,
using Cell Profiler software (www.cellprofiler.org, Broad Institute, Cambridge, MA, USA).
Relative migration capacity was calculated as the change in the area
occupied by cells between 20 and 0 h, normalized by the vehicle control.
Femoral Artery Cuff Model
Male C57BL/6 mice 10 to 12 weeks
old were obtained from Shanghai Center of Experimental Animals (Shanghai,
China). All the mice were housed in temperature- and humidity-controlled
rooms with a 12 h dark/light cycle throughout the study. All procedures
involving animals were approved by the Institutional Animal Care and
Use Committee at Yantai University (IACUC number: 2015-DA-25). The
National Institutes of Health (NIH) Guide for the Care and Use of
Laboratory Animals was followed throughout. Neointima formation was
induced by means of vascular injury through cuff placement around
the femoral artery of mice, as described previously.[27,28] In brief, mice were randomly assigned into three groups: sham-operated
control, cuff-injured control, and cuff injured with 1 treatment. For the cuff-injured groups, a nonconstrictive polyethylene
cuff, 2 mm long (PE-50; Becton-Dickinson, MD, USA), was cut longitudinally,
placed loosely around the right femoral artery, and filled with F-127
pluronic gel (Sigma-Aldrich, Shanghai, China) containing or not containing 1. This gel was prepared in advance by mixing 300 μL
of cold 40% (wt/vol) F-127 pluronic gel dissolved in sterile water
with 100 μL of 20 mM 1 dissolved in DMSO. Cuffs
filled with F-127 pluronic gel containing the solvent vehicle (DMSO),
but lacking 1, were used in cuff-injured control animals.
For the mice with noncuff treatment, the right femoral arteries were
dissected from surrounding tissues, and the respective animals were
used as sham-operated control. The cuff is larger than the vessel
and does not obstruct blood flow. Two weeks after cuff placement,
the cuffed femoral artery was removed after perfusion, fixed in 10%
formalin for 24 h, dehydrated, and embedded in paraffin. Cross sections
were subjected to standard hematoxylin and eosin staining. Photomicrographs
were taken using an Olympus BX51 microscope with an Olympus DP71 CCD
camera (Olympus Corporation, Tokyo, Japan). Quantification analysis
was performed with the software Image-Pro Plus version 6.0 (Media
Cybernetics Inc.).
Statistical Analysis
Statistical
analysis was performed using the ANOVA/Bonferroni test or Student’s t-test (when comparing just two experimental groups). The
number of experiments is given in the figure legends, and all the
data presented in this study are expressed as mean ± SD. All
statistical tests were performed using the GraphPad Prism 4 software
(GraphPad Software Inc.), and a probability value of <0.05 was
considered significant.
Authors: Andrea V Schwaiberger; Elke H Heiss; Muris Cabaravdic; Tina Oberan; Jan Zaujec; Daniel Schachner; Pavel Uhrin; Atanas G Atanasov; Johannes M Breuss; Bernd R Binder; Verena M Dirsch Journal: Arterioscler Thromb Vasc Biol Date: 2010-09-16 Impact factor: 8.311
Authors: Rongxia Liu; Elke H Heiss; Nadine Sider; Andreas Schinkovitz; Barbara Gröblacher; Dean Guo; Franz Bucar; Rudolf Bauer; Verena M Dirsch; Atanas G Atanasov Journal: Mol Nutr Food Res Date: 2015-03-16 Impact factor: 5.914
Authors: Tina Blazevic; Anja M Schaible; Katharina Weinhäupl; Daniel Schachner; Felix Nikels; Christina Weinigel; Dagmar Barz; Atanas G Atanasov; Carlo Pergola; Oliver Werz; Verena M Dirsch; Elke H Heiss Journal: Cardiovasc Res Date: 2013-12-23 Impact factor: 10.787
Authors: Jill Moser; Joris van Ark; Marcory C van Dijk; Dale L Greiner; Leonard D Shultz; Harry van Goor; Jan-Luuk Hillebrands Journal: Sci Rep Date: 2016-10-19 Impact factor: 4.379